USA - NASDAQ:BIOL - US0909117022 - Common Stock
The current stock price of BIOL is 0.129 USD. In the past month the price decreased by -19.73%. In the past year, price decreased by -98.35%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.04 | 217.47B | ||
| ISRG | INTUITIVE SURGICAL INC | 63.62 | 196.37B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.58 | 146.77B | ||
| SYK | STRYKER CORP | 26.86 | 135.27B | ||
| MDT | MEDTRONIC PLC | 16.29 | 115.52B | ||
| IDXX | IDEXX LABORATORIES INC | 56.6 | 57.10B | ||
| BDX | BECTON DICKINSON AND CO | 12.43 | 50.85B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.08 | 48.40B | ||
| RMD | RESMED INC | 25.22 | 36.43B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.16 | 33.86B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 17.01 | 27.19B | ||
| STE | STERIS PLC | 26.35 | 25.61B |
BIOLASE Inc is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Foothill Ranch, California and currently employs 188 full-time employees. BIOLASE, Inc. is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. Its proprietary systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The company offers two categories of laser system products: Waterlase (all-tissue) systems and diode (soft tissue) systems. The Waterlase brand uses a combination of water and laser energy and performs using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. The firm also offers diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. The company also manufactures and sells consumable products and accessories for its laser systems. Its Waterlase and diode systems use disposable laser tips of differing sizes and shapes.
BIOLASE INC
27042 Towne Centre Drive, Suite 270
Foothill Ranch CALIFORNIA 92610 US
CEO: John R. Beaver
Employees: 188
Phone: 19493611200
BIOLASE Inc is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Foothill Ranch, California and currently employs 188 full-time employees. BIOLASE, Inc. is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. Its proprietary systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The company offers two categories of laser system products: Waterlase (all-tissue) systems and diode (soft tissue) systems. The Waterlase brand uses a combination of water and laser energy and performs using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. The firm also offers diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. The company also manufactures and sells consumable products and accessories for its laser systems. Its Waterlase and diode systems use disposable laser tips of differing sizes and shapes.
The current stock price of BIOL is 0.129 USD. The price decreased by -13.19% in the last trading session.
BIOL does not pay a dividend.
BIOL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
BIOL stock is listed on the Nasdaq exchange.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BIOL.
ChartMill assigns a fundamental rating of 1 / 10 to BIOL. Both the profitability and financial health of BIOL have multiple concerns.
Over the last trailing twelve months BIOL reported a non-GAAP Earnings per Share(EPS) of -14.25. The EPS increased by 95.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -111.37% | ||
| ROE | -14222.3% | ||
| Debt/Equity | 41.66 |
9 analysts have analysed BIOL and the average price target is 1.99 USD. This implies a price increase of 1441.86% is expected in the next year compared to the current price of 0.129.
For the next year, analysts expect an EPS growth of 98.59% and a revenue growth 2.98% for BIOL